{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:28:03Z","timestamp":1776400083595,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00520-022-07533-1","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T05:05:58Z","timestamp":1671167158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-4909","authenticated-orcid":false,"given":"Alice","family":"Boileve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Rieutord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Maulard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"7533_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315\u2013352. https:\/\/doi.org\/10.1016\/j.chest.2015.11.026","journal-title":"Chest"},{"key":"7533_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AYY Lee","year":"2003","unstructured":"Lee AYY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146\u2013153. https:\/\/doi.org\/10.1056\/NEJMoa025313","journal-title":"N Engl J Med"},{"key":"7533_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38:496\u2013520. https:\/\/doi.org\/10.1200\/JCO.19.01461","journal-title":"J Clin Oncol"},{"key":"7533_CR4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1055\/a-1450-8178","volume":"121","author":"J Douxfils","year":"2021","unstructured":"Douxfils J, Adcock DM, Bates SM et al (2021) 2021 Update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 121:1008\u20131020. https:\/\/doi.org\/10.1055\/a-1450-8178","journal-title":"Thromb Haemost"},{"key":"7533_CR5","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382:1599\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1915103","journal-title":"N Engl J Med"},{"key":"7533_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"key":"7533_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane","year":"2020","unstructured":"McBane RD, Wysokinski WE, Le-Rademacher JG et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18:411\u2013421. https:\/\/doi.org\/10.1111\/jth.14662","journal-title":"J Thromb Haemost"},{"key":"7533_CR8","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36:2017\u20132023. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034","journal-title":"J Clin Oncol"},{"key":"7533_CR9","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.mayocp.2019.05.035","volume":"94","author":"HE Fuentes","year":"2019","unstructured":"Fuentes HE, McBane RD, Wysokinski WE et al (2019) Direct oral factor Xa inhibitors for the treatment of acute cancer-associated venous thromboembolism: a systematic review and network meta-analysis. Mayo Clin Proc 94:2444\u20132454. https:\/\/doi.org\/10.1016\/j.mayocp.2019.05.035","journal-title":"Mayo Clin Proc"},{"key":"7533_CR10","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","volume":"16","author":"MB Streiff","year":"2018","unstructured":"Streiff MB, Holmstrom B, Angelini D et al (2018) NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw 16:1289\u20131303. https:\/\/doi.org\/10.6004\/jnccn.2018.0084","journal-title":"J Natl Compr Canc Netw"},{"key":"7533_CR11","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1111\/jth.14564","volume":"17","author":"T-F Wang","year":"2019","unstructured":"Wang T-F, Zwicker JI, Ay C et al (2019) The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 17:1772\u20131778. https:\/\/doi.org\/10.1111\/jth.14564","journal-title":"J Thromb Haemost"},{"key":"7533_CR12","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"D Farge","year":"2019","unstructured":"Farge D, Frere C, Connors JM et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20:e566\u2013e581. https:\/\/doi.org\/10.1016\/S1470-2045(19)30336-5","journal-title":"Lancet Oncol"},{"key":"7533_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.critrevonc.2017.10.014","volume":"120","author":"M Crist","year":"2017","unstructured":"Crist M, Hansen E, Chablani L, Guancial E (2017) Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma. Crit Rev Oncol Hematol 120:151\u2013162. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.10.014","journal-title":"Crit Rev Oncol Hematol"},{"key":"7533_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","volume":"10","author":"Y Je","year":"2009","unstructured":"Je Y, Schutz FAB, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967\u2013974. https:\/\/doi.org\/10.1016\/S1470-2045(09)70222-0","journal-title":"Lancet Oncol"},{"key":"7533_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11912-012-0237-9","volume":"14","author":"G Sonpavde","year":"2012","unstructured":"Sonpavde G, Bellmunt J, Schutz F, Choueiri TK (2012) The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep 14:295\u2013306. https:\/\/doi.org\/10.1007\/s11912-012-0237-9","journal-title":"Curr Oncol Rep"},{"key":"7533_CR16","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","volume":"27","author":"M Zangari","year":"2009","unstructured":"Zangari M, Fink LM, Elice F et al (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27:4865\u20134873. https:\/\/doi.org\/10.1200\/JCO.2009.22.3875","journal-title":"J Clin Oncol"},{"key":"7533_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579\u2013591. https:\/\/doi.org\/10.1038\/nrc2403","journal-title":"Nat Rev Cancer"},{"key":"7533_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/cncr.33337","volume":"127","author":"SH Patel","year":"2021","unstructured":"Patel SH, George TL, Wang T-F et al (2021) Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. Cancer 127:938\u2013945. https:\/\/doi.org\/10.1002\/cncr.33337","journal-title":"Cancer"},{"key":"7533_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-017-3386-6","volume":"80","author":"B Liu","year":"2017","unstructured":"Liu B, Ding F, Zhang D, Wei G-H (2017) Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis. Cancer Chemother Pharmacol 80:487\u2013495. https:\/\/doi.org\/10.1007\/s00280-017-3386-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"7533_CR20","doi-asserted-by":"publisher","first-page":"e2061","DOI":"10.1002\/onco.13897","volume":"26","author":"A Sivakumar","year":"2021","unstructured":"Sivakumar A, Caulfield SE, Zhang C et al (2021) Retrospective study of bleeding risk with concomitant vascular endothelial growth factor receptor tyrosine kinase inhibitor and anticoagulation. Oncologist 26:e2061\u2013e2069. https:\/\/doi.org\/10.1002\/onco.13897","journal-title":"Oncologist"},{"key":"7533_CR21","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1111\/jth.15367","volume":"19","author":"T-F Wang","year":"2021","unstructured":"Wang T-F, Baumann Kreuziger L, Leader A et al (2021) Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC subcommittee on hemostasis and malignancy. J Thromb Haemost 19:2068\u20132081. https:\/\/doi.org\/10.1111\/jth.15367","journal-title":"J Thromb Haemost"},{"key":"7533_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","volume":"130","author":"I Mah\u00e9","year":"2017","unstructured":"Mah\u00e9 I, Chidiac J, Bertoletti L et al (2017) The clinical course of venous thromboembolism may differ according to cancer site. Am J Med 130:337\u2013347. https:\/\/doi.org\/10.1016\/j.amjmed.2016.10.017","journal-title":"Am J Med"},{"key":"7533_CR23","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.thromres.2021.11.026","volume":"213","author":"T-F Wang","year":"2022","unstructured":"Wang T-F (2022) Drug-drug interactions: implications for anticoagulation, with focus in patients with cancer. Thromb Res 213:S66\u2013S71. https:\/\/doi.org\/10.1016\/j.thromres.2021.11.026","journal-title":"Thromb Res"},{"key":"7533_CR24","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","volume":"145","author":"CJ Beavers","year":"2022","unstructured":"Beavers CJ, Rodgers JE, Bagnola AJ et al (2022) Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation 145:e811\u2013e838. https:\/\/doi.org\/10.1161\/CIR.0000000000001056","journal-title":"Circulation"},{"key":"7533_CR25","doi-asserted-by":"publisher","first-page":"175883591881834","DOI":"10.1177\/1758835918818347","volume":"11","author":"KGAM Hussaarts","year":"2019","unstructured":"Hussaarts KGAM, Veerman GDM, Jansman FGA et al (2019) Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol 11:1758835918818347. https:\/\/doi.org\/10.1177\/1758835918818347","journal-title":"Ther Adv Med Oncol"},{"key":"7533_CR26","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","volume":"75","author":"BS Wiggins","year":"2020","unstructured":"Wiggins BS, Dixon DL, Neyens RR et al (2020) Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week. J Am Coll Cardiol 75:1341\u20131350. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.068","journal-title":"J Am Coll Cardiol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07533-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07533-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07533-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T19:04:52Z","timestamp":1725995092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07533-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["7533"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07533-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"23 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Gustave Roussy (Date: 15\/02\/2021, No 2021\u201320).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"41"}}